CLYM · Climb Bio, Inc. · Executive Compensation
Market Cap
$818.47M
Shares
57.44M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Aoife Brennan | M.B., Ch B. President and Chief Executive Officer | $2,922,223 |
| Perrin Wilson | Chief Business Officer | $1,537,367 |
| Brett Kaplan | Former Chief Operating Officer | $1,161,728 |
| Susan Altschuller | Ph.D., MBA Chief Financial Officer | $1,151,372 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Aoife Brennan | M.B., Ch B. President and Chief Executive Officer | $6,019,892 |
| Brett Kaplan | Former Chief Operating Officer | $2,989,468 |
| Chief Operating | Officer | $2,989,468 |
| Valerie Morisset | Former Executive Vice President, Research and Development and Chief Scientific Officer | $2,235,295 |
| Andrew Levin | M.D., Ph.D. Former Executive Chair of the Board of Directors | $124,205 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Valerie Morisset | Former Executive Vice President, Research and Development and Chief Scientific Officer | $1,077,620 |
| Andrew Levin | M.D., Ph.D. Former Executive Chair of the Board of Directors | $87,909 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Robert Azelby | — | $5,161,000 |
| Erin M. Lavelle | — | $2,059,455 |
| Valerie Morisset | — | $1,989,782 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Robert Azelby | — | $7,154,787 |
| Erin M. Lavelle | — | $2,545,744 |
| Valerie Morisset | — | $2,525,721 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Valerie Morisset | — | $905,460 |
| Robert Azelby | — | $228,000 |
| Erin M. Lavelle | — | $163,375 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Breanna O'Reilly, Ph.D. | member of the Board | Appointed | 2026-07-01 |
| Andrew Levin | member of the Board | Resigned | 2026-07-01 |
| Douglas Williams | Director | Appointed | 2026-06-08 |
| Alexander (Bo) Cumbo | Director | Appointed | 2026-06-08 |
| Susan Altschuller | principal accounting officer | Appointed | 2026-04-03 |
| Susan Altschuller, Ph.D., MBA | Chief Financial Officer | Appointed | 2025-10-01 |
| Emily Pimblett | Chief Accounting Officer | Resigned | 2025-06-18 |
| Cindy Driscoll | Senior Vice President, Finance of the Company and designated her as the Company's principal financial officer and principal acco | Appointed | 2025-06-18 |
| Aoife Brennan | interim principal financial officer | Appointed | 2025-05-23 |
| Kimberlee (Kim) Drapkin | member of the Board | Appointed | 2025-04-01 |
| Alexander (Bo) Cumbo | member of the Board | Appointed | 2025-04-01 |
| Simon Tate | member of the Company's board of directors | Resigned | 2025-04-01 |
| Andrew Levin | Chairman of the Board | Appointed | 2024-08-27 |
| Brett Kaplan | principal financial officer | Appointed | 2024-08-27 |
| Valerie Morisset | Executive Vice President, Research and Development and Chief Scientific Officer | Terminated | 2024-08-27 |
| Brett Kaplan | Chief Operating Officer | Appointed | 2024-08-26 |
Key facts
CIK
1768446
CUSIP
28658R106
13F (30d)
54 filings
54 filers
Visit website
Investor relations